Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
Pharmacopsychiatry 2006; 39: 21-25
DOI: 10.1055/s-2006-931485
DOI: 10.1055/s-2006-931485
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York
Aripiprazole: Pharmacodynamics of a Dopamine Partial Agonist for the Treatment of Schizophrenia
Further Information
Publication History
Publication Date:
01 March 2006 (online)
![](https://www.thieme-connect.de/media/pharmaco/2006S1/lookinside/thumbnails/10.1055-s-2006-931485-1.jpg)
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2 A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.
References
- 1 Auby P, Saha A R, Ali M W, Ingenito G G, Wilber R, Bramer S L. Safety and Tolerability of Aripiprazole at Doses Higher than 30 mg. Poster presented at 15th European College of Neuropsychopharmacology Congress (ECNP). Barcelona, Spain; October 2002
- 2 Bandelow B. Aripiprazole, a ”Dopamine-Serotonin System Stabilizer” in the Treatment of Psychosis. German Journal of Psychiatry. 2003; 6 9-16
- 3 Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry. 1978; 135 165-173
- 4 Cornblatt B, Kern R S, Carson W H, Dunbar G C, Ali M W, Ingenito G G, Green M F. An Open-Label Comparison Of The Neurocognitive Effects Of Aripiprazole Vs. Olanzapine In Patients With Stable Psychosis. Poster presented at Mount Sinai Conference on Cognition & Schizophrenia. Whistler British Columbia, Canada; April 2001
- 5 de Quervain D J, Henke K, Aerni A, Coluccia D, Wollmer M A, Hock C, Nitsch R M, Papassotiropoulos A. A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci. 2003; 6 1141-1142
- 6 Farde L, Wiesel F A, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988; 45 71-76
- 7 Gründer G, Carlsson A, Wong D F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003; 60 974-977
- 8 Gründer G, Medori R, Kungel M, McQuade R D, Kikuchi T. Aripiprazol: Pharmakologie eines neuen atypischen Antipsychotikums. Der Nervenarzt. 2002; 73(Suppl 1) S191
- 9 Heisler L K, Chu H M, Brennan T J, Danao J A, Bajwa P, Parsons L H, Tecott L H. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A. 1998; 95 15 049-15 054
- 10 Hippius H, Medori R, Kungel M, Saha A R, McQuade R D. Safety and Tolerability of Aripiprazole. Eur Arch Psychiatry Clin Neurosci. 2002; 252(Suppl 1) S51
- 11 Hoyer D, Hannon J P, Martin G R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002; 71 533-554
- 12 Hoyer D, Pazos A, Probst A, Palacios J M. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res. 1986; 376 85-96
- 13 Kane J M, Carson W H, Saha A R, McQuade R D, Ingenito G G, Zimbroff D L, Ali M W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63 763-771
- 14 Kasper S, Lerman M N, McQuade R D, Saha A, Carson W H, Ali M W, Archibald D G, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6 325-337
- 15 Marder S R, McQuade R D, Stock E G, Kaplita S B, Marcus R, Safferman A Z, Saha A, Ali M W, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003; 61 123-136
- 16 McQuade R D, Burris K D, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: A Dopamine-Serotonin System Stabilizer. Int J Neuropsychopharmacol. 2002; 5(Suppl 1) 176
- 17 Meltzer H Y, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors : their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27 1159-1172
- 18 Müller W E. Partieller D2-Agonismus und dopaminerge Stabilisierung durch Aripiprazol. Psychopharmakotherapie. 2002; 9 120-126
- 19 Pigott T A, Carson W H, Saha A R, Torbeyns A F, Stock E G, Ingenito G G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64 1048-1056
- 20 Potkin S G, Saha A R, Kujawa M J, Carson W H, Ali M W, Stock E G, Stringfellow J, Ingenito G, Marder S R. Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder. Arch Gen Psychiatry. 2003; 60 681-690
- 21 Rüther E. Schizophrenietherapie im Wandel der Zeit. psycho. 2002; 28 539-543
- 22 Yokoi F, Gründer G, Biziere K, Stephane M, Dogan A S, Dannals R F, Ravert H, Suri A, Bramer S, Wong D F. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14 597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002; 27 248-259
Prof. Dr. med. Gerhard Gründer
Klinik für Psychiatrie und Psychotherapie
Universitätsklinikum Aachen
RWTH Aachen
Pauwelsstr. 30
D-52074 Aachen
Germany
Phone: 0241-8088415
Fax: 0241-803388415
Email: ggruender@ukaachen.de